Literature DB >> 2574630

Cancer patients' lymphocytes contain CD3+ CD4+ cells that proliferate in response to autologous tumor cells in the presence of exogenous low-dose interleukin-2 and autologous accessory cells.

M Radrizzani1, M Quaia, B Benedetti, S Andreola, M Vaglini, E Galligioni, G Fossati, G Parmiani.   

Abstract

To see whether cancer patients possess CD3+ CD4+ lymphocytes able to proliferate in response to autologous tumor cells (Auto-Tu), this lymphocyte subset was isolated either by positive or negative selection, both methods resulting in highly enriched CD4+ populations. Unseparated and isolated CD3+ CD4+ lymphocytes were then assayed for proliferating activity in the presence or absence of various amounts of Auto-Tu, with or without recombinant interleukin-2 (IL-2) (1.5-15 U/ml) and DR+ adherent cells or E- lymphocytes as autologous accessory cells (Auto-AC). Isolated CD3+ CD4+ lymphocytes were stimulated by Auto-Tu alone in only 1 out of 12 cases. CD3+ CD4+ cells failed to proliferate significantly in response to low doses of IL-2 alone but the addition of Auto-Tu caused stimulation in 8 out of 12 cases (67%). The further addition of Auto-AC to Auto-Tu + IL-2 resulted in enhanced response of isolated CD3+ CD4+ lymphocytes in 6 out of 8 cases tested. When reactivities to Auto-Tu in the presence of IL-2 and IL-2 + Auto-AC were considered together, positive responses of CD3+ CD4+ lymphocytes were seen in 11 out of 12 cases (92%). On the other hand, unseparated lymphocytes were stimulated by Auto-Tu alone in none out of 12 cases. Unseparated lymphocytes, however, responded to IL-2 in 11 out of 12 cases; such a response was increased by the addition of Auto-Tu in only 2 cases. Moreover, the IL-2 proliferation of unseparated lymphocytes was suppressed in 4 and in 3 out of 12 cases tested when Auto-Tu or Auto-Tu + Auto-AC were added respectively. These data indicate that lymphocytes of cancer patients contain CD3+ CD4+ cells that are usually unable to proliferate in response to Auto-Tu only. This proliferation, however, occurs when low doses of exogenous IL-2 are present and can be further amplified by the addition of Auto-AC. No response of CD4+ cells is observed in the presence of DR+ Auto-AC + IL-2 except in 2 out of 7 cases tested (28%), suggesting an Auto-Tu-restricted reactivity of CD3+ CD4+ lymphocytes in the majority of cases.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2574630     DOI: 10.1007/bf01665010

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  30 in total

Review 1.  Signal transduction in human T lymphocytes.

Authors:  D C Linch; D L Wallace; K O'Flynn
Journal:  Immunol Rev       Date:  1987-02       Impact factor: 12.988

2.  Requirement for recognition of class II molecules and processed tumor antigen for optimal generation of syngeneic tumor-specific class I-restricted CTL.

Authors:  D E Kern; J P Klarnet; M C Jensen; P D Greenberg
Journal:  J Immunol       Date:  1986-06-01       Impact factor: 5.422

3.  CD4+ helper T cells are required for resistance to a highly metastatic murine tumor.

Authors:  H J Schild; B Kyewski; P Von Hoegen; V Schirrmacher
Journal:  Eur J Immunol       Date:  1987-12       Impact factor: 5.532

4.  In vitro reeducated T helper cells from sarcoma-bearing mice inhibit sarcoma growth in vivo.

Authors:  G Forni; M Giovarelli
Journal:  J Immunol       Date:  1984-01       Impact factor: 5.422

5.  Tumor cell-triggered macrophage-mediated suppression of the T-cell cytotoxic response to tumor-associated antigens. I. Characterization of the cell components for induction of suppression.

Authors:  C C Ting; D Rodrigues
Journal:  J Natl Cancer Inst       Date:  1982-10       Impact factor: 13.506

6.  Distinct forms of both alpha and beta subunits are present in the human Ia molecular pool.

Authors:  R S Accolla; N Gross; S Carrel; G Corte
Journal:  Proc Natl Acad Sci U S A       Date:  1981-07       Impact factor: 11.205

7.  Cellular basis of immunologic interactions in adoptive T cell therapy of established metastases from a syngeneic murine sarcoma.

Authors:  B A Ward; S Shu; T Chou; D Perry-Lalley; A E Chang
Journal:  J Immunol       Date:  1988-08-01       Impact factor: 5.422

Review 8.  Activation of lymphocyte anti-tumour responses in man: effector heterogeneity and the search for immunomodulators.

Authors:  B M Vose
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

9.  The inhibition of lymphocyte stimulation by autologous human metastatic melanoma cells correlates with the expression of HLA-DR antigens on the tumor cells.

Authors:  D Taramelli; G Fossati; A Balsari; R Marolda; G Parmiani
Journal:  Int J Cancer       Date:  1984-12-15       Impact factor: 7.396

10.  Characterization of cells from invaded lymph nodes in patients with solid tumors. Lymphokine requirement for tumor-specific lymphoproliferative response.

Authors:  F Cozzolino; M Torcia; A M Carossino; R Giordani; C Selli; G Talini; E Reali; A Novelli; V Pistoia; M Ferrarini
Journal:  J Exp Med       Date:  1987-08-01       Impact factor: 14.307

View more
  1 in total

1.  Clonal analysis of peripheral blood lymphocytes from three patients with advanced neuroblastoma receiving recombinant interleukin-2 and interferon alpha.

Authors:  I Prigione; P Facchetti; E Lanino; A Garaventa; V Pistoia
Journal:  Cancer Immunol Immunother       Date:  1993-07       Impact factor: 6.968

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.